SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Neotherapuetics possibly has a breakthrough drug - NEOT
NEOT 1.919+4.3%Jan 17 4:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Marty who started this subject3/1/2001 2:46:57 PM
From: Marty   of 204
 
Here is a response posted on Raging Bull to the press release on Reminyl:

-----------------

Thanks, TTB, for posting the press release on Reminyl. It seems to me that the crucial difference between it (and Aricept and the others as a matter of fact) is the comparison of their results to patients on placebo. They said it three different times:

"In studies lasting up to six months, many patients' symptoms initially improved or stabilized, and even when they begin to decline, they remained better than those treated with placebo..."

and

"Across all studies, the results consistently demonstrated that more patients taking Reminyl showed significant improvement in their cognitive performance than those receiving placebo."

and

"The CIBIC-plus results from all studies also showed that the overall scores for patients taking Reminyl were statistically superior to placebo."

The fact that they never mention is that Alzheimer patients taking placeboes DECLINE over time. The degenerative process continues … about 1.6 ADAS cog points a year, as I recall. WHAT THEY ARE SAYING IS THAT THE PATIENTS TAKING REMINYL DECLINE LESS OVER TIME THAN UNTREATED PATIENTS.

The tests on Neotrofin, on the other hand, indicate that the patients improve over their baseline. In other words, they actually functioned BETTER than they did when they began the trials. (That's how you get the story about the AD patient taking Neotrofin who was released from the nursing facility to go home.)

Note the difference in NEOT's press release last November:

"On Thursday, the company said the study's results showed that patients who were suffering from more moderate Alzheimer's disease and who received the 500 milligram dose level of Neotrofin improved an average 1.5 points from baseline on the Alzheimer's Disease Assessment Scale-cognitive subscale after 90 days of treatment."

That is an improvement over BASELINE after 90 days.

I saw this comparison chart at the last shareholder's annual meeting. I hope they will put it up on their website with sufficient explanations of this fundamental difference. This is not another "me-too" drug, but a dramatically different approach and result.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News